Leukemia Clinical Trials & Research for Children

Clinical trials have formed the foundation of virtually every advance made in cancer care. Trials can offer hope when standard therapies are no longer effective. MSK Kids offers a range of clinical trials assessing investigational approaches for children with leukemia. We have trials for cancer that has continued growing or has come back after treatment. These include studies assessing immunotherapies. These treatments boost the power of the immune system to find and kill cancer cells. We also study new drugs and stem cell transplantation techniques.

Your child’s care team will let you know if your child can participate in a clinical trial. The decision to enroll is entirely voluntary. The study team will explain the benefits and risks of the study to you so you can make an informed decision.

and/or
Reset
22 Clinical Trials found
A Phase 2 Study of Venetoclax and Revumenib in People With Acute Myeloid Leukemia
Venetoclax blocks Bcl-2, a protein that helps cancer cells survive and resist the effects of anti-cancer treatments. By blocking Bcl-2, venetoclax may cause the death of cancer cells or make them more sensitive to other treatments. It is taken orally (by mouth).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study Assessing Dasatinib or Imatinib and Chemotherapy With and Without Blinatumomab for Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
New York City
A Phase 3 Study of Inotuzumab Ozogamicin and Standard Chemotherapy for Newly Diagnosed High-Risk B-Cell Acute Lymphocytic Leukemia, Mixed Acute Leukemia, and Disseminated B-LLy
The overall goal of this study is to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves treatment effectiveness in young patients with high-risk B cell acute lymphoblastic leukemia (B-ALL). Inotuzumab ozogamicin contains an antibody (inotuzumab) linked to a type of chemotherapy (calicheamicin). Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them.
New York City
A Phase 3 Study of Standard Chemotherapy with or without Venetoclax in Children and Adolescents with Relapsed Acute Myeloid Leukemia
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I Study of UCART22 CAR T-Cell Therapy in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
New York City
A Phase II Study of Inotuzumab Ozogamicin in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
Inotuzumab ozogamicin is a drug used to treat adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite prior therapy. In this study, researchers are evaluating its use in children and young adults with recurrent or persistent B-cell ALL.
New York City
A Phase III Study Comparing Standard Chemotherapy to Treatment with CPX-351 and/or Gilteritinib for Children Newly Diagnosed with Acute Myeloid Leukemia
Daunorubicin, cytarabine, and gemtuzumab ozogamicin are different chemotherapy drugs used to treat acute myeloid leukemia (AML). CPX-351 is made up of daunorubicin and cytarabine. It is created in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drugs used in cancer care.
New York City
A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders
The transplantation of stem cells from umbilical cord blood is a treatment for some blood cancers and non-cancerous blood or metabolic disorders. Patients routinely receive high doses of chemotherapy and sometimes radiation before receiving the stem cells to help make room in the bone marrow for new blood stem cells to grow, prevent the body from rejecting the transplanted cells, and help kill any abnormal blood cells in the body. However, the combination of these treatments can have serious side effects.
New York City
A Study of CTD402 in People With T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Study of Revumenib and Mezigdomide in People With Leukemia
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau